Simon Istolainen

Founder @ CURE51, the world’s 1st clinical and multiomics discovery platform focused on exceptional cancer survivors. TechBio investor (OWKIN, RESILIENCE), Partner at MEDIAWAN, and Board Advisor @ STATION F

📍 Greater Paris Metropolitan Region, France🔄 Updated September 2026💼 6 investments📅 16 years investing🗓 Last invested Mar 2021
Operator-angel🌍 France
6
Total investments
3
Early stage
0
Mid stage
0
Late stage
16y
Years active

Portfolio

5 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Seed Investor
Mar 2021
Resilience Care, a major player in remote patient monitoring and a partner in clinical research, is a French company founded in 2021 with one mission: to provide better care. The company offers remote monitoring solutions in oncology, gastroenterology, and psychiatry, which are routinely used by 23,000 patients in more than 150 healthcare facilities and in more than 20 academic and industrial clinical studies. Resilience Care harnesses data for healthcare and therapeutic innovation with the ambition of enabling every patient with a chronic disease to benefit from personalized medicine. The Resilience Oncology remote patient monitoring solution is dedicated to cancer patients (all cancers, all stages, and all treatments). It combines two tools: A monitoring platform for healthcare professionals (CE Class IIa certified medical device) that enables early detection of side effects and improves patient care. A mobile app for patients that allows them to report their symptoms and benefit from personalized resources throughout their care journey.
Shareholder
Nov 2017
Owkin is building the first BASI to unlock breakthroughs in therapies, diagnostics, and rejuvenation, while reshaping how humanity understands and engineers biology. Like other frontier AI companies, we believe the leap from narrow tools to true reasoning systems marks the start of a new era — where intelligence is not just assisting scientists but autonomously advancing discovery. Owkin’s moats are structural and compounding. We are creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. Exclusive partnerships with world-class hospitals, unique longitudinal datasets, and automated lab infrastructure create a defensibility flywheel similar to the data moats seen in other generational AI companies. By uniting reasoning models, agentic workflows, and living biological systems, Owkin is building the operating system for biology — a platform no one else can replicate, and the inevitable leader in general-purpose biology intelligence.
Investor
Dec 2015
MARKS LIMITED is an airlines/aviation company based out of 1A HIGH STREET LENHAM, MAIDSTONE, KENT, United Kingdom.
Shareholder
Jul 2014
Since 2014, La Compagnie, the all-business class airline that is reinventing your business class experience features 76 spacious full-flat seats, state of the art entertainment system, wifi unlimited wifi, and seasonal cuisine made by the famous French Chef, Christophe Langree. La Compagnie operates daily all-business-class flights with 2 Airbus A321neo between Paris and New York since July, 2014, between Nice and New York from 2019 and will open a new route from New York to Milan from April 2022. Please visit www.lacompagnie.com.
Shareholder
May 2010
You've been waiting for it? here it is: the unique social network for you around the world who what to have a chat around a bottle of wine, meet, and also buy your wine on the web ! Already in 2 langages, watch out, in a couple of weeks, several other langages will also be available !
Experience · 11 entries
All (11)
Investments (6)
Founder (3)
2022
Co-Founder
Dec 2022
The first worldwide clinical and molecular database of exceptional survivors leading the path to new therapies against cancer.
2021
Seed Investor
Mar 2021
Resilience Care, a major player in remote patient monitoring and a partner in clinical research, is a French company founded in 2021 with one mission: to provide better care. The company offers remote monitoring solutions in oncology, gastroenterology, and psychiatry, which are routinely used by 23,000 patients in more than 150 healthcare facilities and in more than 20 academic and industrial clinical studies. Resilience Care harnesses data for healthcare and therapeutic innovation with the ambition of enabling every patient with a chronic disease to benefit from personalized medicine. The Resilience Oncology remote patient monitoring solution is dedicated to cancer patients (all cancers, all stages, and all treatments). It combines two tools: A monitoring platform for healthcare professionals (CE Class IIa certified medical device) that enables early detection of side effects and improves patient care. A mobile app for patients that allows them to report their symptoms and benefit from personalized resources throughout their care journey.
2017
Shareholder
Nov 2017
Owkin is building the first BASI to unlock breakthroughs in therapies, diagnostics, and rejuvenation, while reshaping how humanity understands and engineers biology. Like other frontier AI companies, we believe the leap from narrow tools to true reasoning systems marks the start of a new era — where intelligence is not just assisting scientists but autonomously advancing discovery. Owkin’s moats are structural and compounding. We are creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. Exclusive partnerships with world-class hospitals, unique longitudinal datasets, and automated lab infrastructure create a defensibility flywheel similar to the data moats seen in other generational AI companies. By uniting reasoning models, agentic workflows, and living biological systems, Owkin is building the operating system for biology — a platform no one else can replicate, and the inevitable leader in general-purpose biology intelligence.
Partner
Jul 2017
Mediawan is the premier independent European studio behind major international successes such as Miraculous, HIP, Call My Agent!, The Count of Monte Cristo, 3 Body Problem, Beetlejuice Beetlejuice, One Day, and many others. A collective of more than 80 production companies present in 13 countries across Europe, America, Asia, and Africa, combining freedom, creative excellence, and unique perspectives. From production to distribution and diversification activities, Mediawans sole ambition is to showcase creativity in all genres (Series, Unscripted, Documentary, Cinema, Animation...). Our European roots shape who we are but our vision extends globally. Our mission is to craft narratives that resonate with global audiences. We have built a company where the worlds best creatives can realize their boldest vision because we believe that outstanding stories come from unique talents.
2015
Investor
Dec 2015
MARKS LIMITED is an airlines/aviation company based out of 1A HIGH STREET LENHAM, MAIDSTONE, KENT, United Kingdom.
Show all 11 entries ↓
Investment activity
2010–2021 · 6 investments
201012011120141201512017120211
Recent (last 2 years)Earlier